Clinical trials: IgG4 Related Disease
IgG4 Related Disease, B-cell Mediated Autoimmune Disorders
Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease
The goal of this clinical trial is to test the safety and potential benefit of a new immune cell therapy called anti-BCMA-CD19 CAR-T cells in adults (18-75 years) with IgG4-related disease (IgG4-RD) that has come back or not…
- Trial name
- BC19IGG4 (NCT07148791)
- Testing
- Anti-BCMA-CD19 CAR-T cells
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Chinese PLA General Hospital
Giant Cell Arteritis (GCA), Polymyalgia Rheumatica (PMR)
AYLo - AutoimmunitY and Loss of y
The AYLo study (AutoimmunitY and Loss of y - Investigating the Role of Hematopoietic Mutations and Mosaic Mutation in the Y Chromosome in Autoimmune Rheumatologic Diseases) aims to systematically investigate hematopoietic…
- Conditions
- Giant Cell Arteritis (GCA), Polymyalgia Rheumatica (PMR), ANCA Associated Vasculitis (AAV), Idiopathic Inflammatory Myopathies
- Trial name
- AYLo (NCT06696027)
- Testing
- Single nucleotide polymorphisms (SNP), 3'mRNA sequencing, Enzyme-linked immunosorbent assay (ELISA) and Legendplex Array
- Where
- Germany
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- University of Bonn
IgG4-related Disease
A Prospective Cohort Study of IgG4RD in China
This is an cohort study to investigate the disease course and treatment response of patients with IgG4-related disease.
- Trial name
- NCT01670695
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Peking Union Medical College Hospital
IgG4-Related Disease
A Study of IMM0306 in IgG4-Related Disease
The goal of this clinical trial is to learn if IMM0306 works to reduce the risk of disease relapse in participants with IgG4-related disease (IgG4-RD). It will also learn about the safety and tolerability of IMM0306.
- Trial name
- NCT07621939
- Testing
- IMM0306
- Volunteers
- 125 people
- Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Immunoglobulin G4-Related Disease
Study of the C5a/C5aR1 Axis in IgG4-associated Disease: a Potential Therapeutic Target
This is a monocentric, comparative, cross-sectional, case-control study seeking to identify abnormalities of the C5a-C5aR1 axis between a population of patients with active IgG4-associated disease (MAG4) and two control groups…
- Trial name
- C5-MAG4 (NCT06270524)
- Testing
- Blood sampling
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Assistance Publique Hopitaux De Marseille
Immunoglobulin G4-related Disease
Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD
The primary objectives of this study are to characterize the pharmacokinetics (PK) and pharmacodynamics (PD), as well as to assess the safety and tolerability, of inebilizumab in pediatric participants with IgG4-RD.
- Trial name
- NCT07222553
- Testing
- Inebilizumab
- Where
- 14 sites in United States, Brazil and 5 more
- Volunteers
- 15 people
- Sponsor
- Amgen
Immunoglobulin G Subclass 4 Related Disease, IgG4-related Disease
Treatment of IgG4-Related Disease With Revlimid and Rituximab
Among persons with Immunoglobulin G subclass 4 Related Disease (IgG4)-related disease who have persistent or recurrent disease despite standard therapies, does combination therapy with rituximab and revlimid cause a sustained…
- Conditions
- Immunoglobulin G Subclass 4 Related Disease, IgG4-related Disease, Autoimmune Pancreatitis, IgG4-related Sclerosing Cholangitis
- Trial name
- TIGR2 (NCT02705638)
- Testing
- Rituximab, Lenalidomide
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Mayo Clinic
AMG 335 Expanded Access Program for IgG4-Related Disease
Expanded access requests for AMG 335 may be considered for adult patients with a confirmed diagnosis of IgG4-related disease. To request access, use Responsible Party contact information provided in this record.
- Trial name
- NCT06590051
- Testing
- UPLIZNA
- Sponsor
- Amgen
Autoimmune Diseases
Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement
This study has been designed as a 12-month, open-label randomized controlled clinical trial. The study aims to compare the efficacy and safety of two treatment strategies in IgG4-RD patients with superficial organ involvement…
- Trial name
- NCT05789030
- Testing
- glucocorticoid plus iguratimod, glucocorticoid plus leflunomide
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College Hospital
IgG4-related Disease
Plasmablast Detection From IgG4-Related Disease Patients
IgG4-related disease (IgG4-RD) is an immune-mediated, fibro-inflammatory disease that leads to tissue damage, organ dysfunction and, if untreated, to organ failure.
- Trial name
- NCT03466970
- Where
- 2 sites in Israel
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Meir Medical Center
Fever of Unknown Origin, IgG4 Related Disease
The Investigators Will Evaluate the Diagnostic Performance of [18F]-AlF-FAPI-74 PET/CT in Inflammatory Disorders and Compare it With the Current Gold Standard for Inflammation, FDG PET/CT, in Three Patient Cohort: Patients Presenting With Fever of Unknown Origin, IgG4-RD and AxSpA.
The aim of the study to evaluate the performance of new [18F]-AlF-FAPI-74 PET/CT in three inflammatory disorders (fever of unknown origin, IgG4-related disease and axial spondyloarthritis) and compare with the current…
- Conditions
- Fever of Unknown Origin, IgG4 Related Disease, Axial Spondylarthritis (axSpA), Inflammation of Unknown Origin
- Trial name
- NCT07535554
- Testing
- [18F]AlF-FAPI-74 PET/CT
- Where
- Belgium
- Volunteers
- 140 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Autoimmune Diseases
Treatment Strategies in IgG4-RD Patients With Re-elevation of Serum IgG4 Level During Maintenance Remission Period
This study has been designed as a 52-week, randomized double blind placebo controlled multicenter clinical trial. The study aims to compare the efficacy and safety of two treatment strategies in IgG4-RD patients with re-elevation…
- Trial name
- NCT05974683
- Testing
- mycophenolate mofetil
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Peking Union Medical College Hospital
IgG4-Related Diseases
Key Mechanisms of Abnormal T Cell Activation and Differentiation in IgG4-Related Ophthalmic Disease
IgG4-related disease (IgG4-RD) is a newly recognized chronic inflammatory condition caused by immune system dysfunction. It is characterized by the infiltration of IgG4+ plasma cells, dense fibrosis, and inflammation involving…
- Trial name
- NCT06655831
- Volunteers
- 20 people
- Sponsor
- Peking University Third Hospital
IgG4 Related Disease
Adaptive and Trained Immunity in the Pathogenesis of IgG4-Related Disease
Enquire involvement of trained immunity in the pathogenesis of IgG4RD
- Trial name
- TRIM4 (NCT06844864)
- Where
- Italy
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Systemic Lupus Erythematosus, Autoimmune Hemolytic Anemia
UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
This is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in With Relapse/Refractory Autoimmune Diseases.
- Conditions
- Systemic Lupus Erythematosus, Autoimmune Hemolytic Anemia, Myasthenia Gravis, Systemic Sclerosis
- Trial name
- NCT06978738
- Testing
- universal allogeneic anti-CD19/BCMA CAR T-cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Changzhou No.2 People's Hospital
IgG4-RD
Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD)
The purpose of this Phase 2 study is to investigate the effect of XmAb5871 on IgG4-Related Disease (RD) activity
- Trial name
- NCT02725476
- Testing
- XmAb5871
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Xencor, Inc.
IgG4-related Disease
BCT301 in Treating Refractory/Recurrent IgG4-related Disease
This is an investigator initiated trial to assess the safety and efficacy of BCT301 cell Injection (CAR-iT cells derived from chemically induced pluripotent stem cells) in patients with refractory/recurrent IgG4-related disease.
- Trial name
- NCT07793903
- Testing
- BCT301 Cell Injection
- Volunteers
- 6 people
- Sponsor
- Peking University Third Hospital
Autoimmune Pancreatitis, IgG4-Related Diseases
Validation of the Odesa Criteria 2026 for Autoimmune Pancreatitis
This ambispective observational study aims to validate the Odesa Criteria 2026 (OC26), a flexible domain-based point scoring system for diagnosing autoimmune pancreatitis.
- Conditions
- Autoimmune Pancreatitis, IgG4-Related Diseases, Pancreatic Cancer, Chronic Pancreatitis
- Trial name
- ОС26 (NCT07536841)
- Testing
- No intervention (observational study)
- Where
- 2 sites in Ukraine
- Volunteers
- 82 people
- Sponsor
- Military Medical Clinical Center of the Southern Region, Ukraine
IgG4-related Disease
Follicular Helper T Cells: Biological Marker and Involvement in the Physiopathology of the IgG4-related Disease
IgG4-related disease is a rare and very recently identified pathology, whose frequency is certainly underestimated. The clinical presentation varies among affected organs, and most often, patients have at least three organ…
- Trial name
- G4-FH (NCT02899039)
- Testing
- extra blood draw samples
- Where
- France
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Assistance Publique Hopitaux De Marseille
Disease Immunoglobulin G4
Characterization of Tissular T Follicular Helper Cells in IgG4-RD
IgG4-related disease (IgG4-RD) is a recently identified rare disease characterized by inflammatory lesions with polyclonal lymphoplasmocytic infiltrate, with IgG4+ plasma cells predominance, and fibrosis in involved tissues.
- Trial name
- TIFOLH4 (NCT02872441)
- Testing
- blood sample
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Assistance Publique Hopitaux De Marseille